The potential of lignanamides in Alzheimer’s disease treatment was tested by verifying its effect on BACE 1, PPARγ, and PGC-1α expression in amyloid β precursor protein (APP)-producing N2a cells. This evidence concerns the gene PPARGC1A and early-onset autosomal dominant Alzheimer disease.